Related Experiment Video
Updated: Jul 19, 2026
10:04
Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis
Published on: May 1, 2015
New horizons in multiple myeloma therapy.
Edgardo S Santos1, Mohamed A Kharfan-Dabaja
1Tulane University Health Sciences Center, Division of Hematology-Medical Oncology, 1430 Tulane Avenue, SL-78 New Orleans, LA 70112, USA. esantos1@tulane.edu
Expert Review of Anticancer Therapy
|October 31, 2006
Summary
Recent breakthroughs in understanding multiple myeloma biology have led to new treatments targeting cancer cells and their environment. This review covers current and emerging therapies for multiple myeloma management.
Area of Science:
- Hematology
- Oncology
- Molecular Biology
Background:
- Multiple myeloma is a complex blood cancer originating from plasma cells.
- Understanding the molecular and biological underpinnings of myeloma has been limited.
- Previous treatments focused primarily on targeting myeloma cells directly.
Purpose of the Study:
- To review novel therapeutic agents for multiple myeloma.
- To evaluate the role of these agents in various disease settings (newly diagnosed, relapsed/refractory).
- To provide an overview of emerging therapies transitioning from research to clinical practice.
Main Methods:
- Literature review of recent advances in multiple myeloma treatment.
- Analysis of therapeutic strategies targeting both myeloma cells and their microenvironment.
- Evaluation of clinical data for novel agents in different patient populations.
Main Results:
- New understanding of myeloma pathobiology enables targeted therapies.
- Novel agents show promise when used alone or in combination.
- Therapies are being investigated for induction, relapsed, and refractory multiple myeloma.
Conclusions:
- Advances in molecular and biological understanding are transforming multiple myeloma treatment.
- Targeted therapies, including those addressing the microenvironment, offer new hope.
- Ongoing research is paving the way for future clinical applications of novel agents.
Related Concept Videos
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:50Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:50Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...